Industry Research Reports

Home > Reports > Medical Care > Human Oocyte Cryopreservation- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Human Oocyte Cryopreservation- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-11-29

Pages: 121 Pages

Report ld: 3389761

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Human Oocyte Cryopreservation was estimated to be worth US$ 82 million in 2023 and is forecast to a readjusted size of US$ 210 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030.

Human oocyte cryopreservation (egg freezing) is a procedure to preserve female eggs (oocytes). The eggs are extracted, frozen and stored. The purpose of the procedure is to give women the option of thawing, fertilizing and transplanting the eggs into the uterus as embryos to promote future pregnancy.

Human Oocyte Cryopreservation Market Size

M= millions and B=billions

Oocyte cryopreservation refers to the technology of cooling human oocytes and storing them in liquid nitrogen (generally stored in liquid nitrogen at -196°C), resuscitating (thawing) them when needed, and ensuring that the oocytes are alive and functioning normally. It is a derivative technology of assisted reproductive technology, mainly used to treat infertility and preserve female fertility.

The driving factors of the oocyte cryopreservation market mainly include the following aspects:
Technological progress
The continuous improvement and maturity of oocyte cryopreservation technology has improved the recovery rate and survival rate of frozen oocytes, thereby increasing the clinical application prospects of this technology and driving the development of the market.

Changes in fertility concepts
The changes in modern women's fertility concepts and the intensification of the trend of late marriage and late childbearing have led more and more women to choose oocyte cryopreservation technology to maintain fertility and provide guarantees for future fertility plans.

Growth in medical demand
With the improvement of medical standards and people's attention to reproductive health, more and more medical institutions and patients have begun to pay attention to oocyte cryopreservation technology, which has promoted the rapid development of the market.

Policy support
The support policies of some countries and regions for assisted reproductive technology, as well as the improvement of relevant laws and regulations, have provided a good policy environment for the development of oocyte cryopreservation technology.

Unlike sperm, oocytes are larger and contain a lot of water, which makes it easier to form ice crystals that may damage the eggs during the freezing process. In addition, egg extraction is not easy and the number is scarce, so the selection of protective agents during the freezing process is also more demanding. These factors have made egg freezing one of the difficulties in freezing technology.

However, with the continuous advancement of technology, the success rate of oocyte cryopreservation has been significantly improved. International clinical trials have proven that frozen eggs can be stored for at least ten years, and they still have the ability to conceive after thawing, can form healthy embryos, and can normally conceive babies. This has led more and more women to choose to preserve their future reproductive ability through oocyte cryopreservation technology, that is, to buy a "fertility insurance".

In general, oocyte cryopreservation technology provides an effective option for women who want to preserve their fertility, and also provides new possibilities for the development of assisted reproductive technology.

The Human Oocyte Cryopreservation market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Oocyte Cryopreservation.

Market Segmentation

Report Metric
Details
Report Title
Human Oocyte Cryopreservation- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 210 million
CAGR(2024-2030)
15%
Market Size Available for Years
2019-2030
Global Human Oocyte Cryopreservation Companies Covered
Anova Fertility, CCRM IVF, Chill, CREATE Fertility, Extend Fertility, HRC Fertility, IVF Australia, Kindbody, London Women’s Clinic, Manchester Fertility, Mayo Clinic, Melbourne IVF, Monash IVF, Pacific Fertility Center-Los Angeles (PFCLA), PIVET, Prelude Fertility
Global Human Oocyte Cryopreservation Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Oocyte Cryopreservation Market, Segment by Type
Slow-cooling Method

Flash-freezing Process (Vitrification)
Global Human Oocyte Cryopreservation Market, Segment by Application
25-30 Year Old Female

30-35 Year Old Female

35-40 Year Old Female

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Oocyte Cryopreservation company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Human Oocyte Cryopreservation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Human Oocyte Cryopreservation in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Human Oocyte Cryopreservation Product Introduction
    1.2 Global Human Oocyte Cryopreservation Market Size Forecast (2019-2030)
    1.3 Human Oocyte Cryopreservation Market Trends & Drivers
        1.3.1 Human Oocyte Cryopreservation Industry Trends
        1.3.2 Human Oocyte Cryopreservation Market Drivers & Opportunity
        1.3.3 Human Oocyte Cryopreservation Market Challenges
        1.3.4 Human Oocyte Cryopreservation Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Human Oocyte Cryopreservation Players Revenue Ranking (2023)
    2.2 Global Human Oocyte Cryopreservation Revenue by Company (2019-2024)
    2.3 Key Companies Human Oocyte Cryopreservation Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Human Oocyte Cryopreservation Product Offered
    2.5 Key Companies Time to Begin Mass Production of Human Oocyte Cryopreservation
    2.6 Human Oocyte Cryopreservation Market Competitive Analysis
        2.6.1 Human Oocyte Cryopreservation Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Human Oocyte Cryopreservation Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Oocyte Cryopreservation as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Slow-cooling Method
        3.1.2 Flash-freezing Process (Vitrification)
    3.2 Global Human Oocyte Cryopreservation Sales Value by Type
        3.2.1 Global Human Oocyte Cryopreservation Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Human Oocyte Cryopreservation Sales Value, by Type (2019-2030)
        3.2.3 Global Human Oocyte Cryopreservation Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 25-30 Year Old Female
        4.1.2 30-35 Year Old Female
        4.1.3 35-40 Year Old Female
        4.1.4 Others
    4.2 Global Human Oocyte Cryopreservation Sales Value by Application
        4.2.1 Global Human Oocyte Cryopreservation Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Human Oocyte Cryopreservation Sales Value, by Application (2019-2030)
        4.2.3 Global Human Oocyte Cryopreservation Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Human Oocyte Cryopreservation Sales Value by Region
        5.1.1 Global Human Oocyte Cryopreservation Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Human Oocyte Cryopreservation Sales Value by Region (2019-2024)
        5.1.3 Global Human Oocyte Cryopreservation Sales Value by Region (2025-2030)
        5.1.4 Global Human Oocyte Cryopreservation Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Human Oocyte Cryopreservation Sales Value, 2019-2030
        5.2.2 North America Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Human Oocyte Cryopreservation Sales Value, 2019-2030
        5.3.2 Europe Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Human Oocyte Cryopreservation Sales Value, 2019-2030
        5.4.2 Asia Pacific Human Oocyte Cryopreservation Sales Value by Region (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Human Oocyte Cryopreservation Sales Value, 2019-2030
        5.5.2 South America Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Human Oocyte Cryopreservation Sales Value, 2019-2030
        5.6.2 Middle East & Africa Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Human Oocyte Cryopreservation Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Human Oocyte Cryopreservation Sales Value, 2019-2030
    6.3 United States
        6.3.1 United States Human Oocyte Cryopreservation Sales Value, 2019-2030
        6.3.2 United States Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Human Oocyte Cryopreservation Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Human Oocyte Cryopreservation Sales Value, 2019-2030
        6.4.2 Europe Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Human Oocyte Cryopreservation Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Human Oocyte Cryopreservation Sales Value, 2019-2030
        6.5.2 China Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Human Oocyte Cryopreservation Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Human Oocyte Cryopreservation Sales Value, 2019-2030
        6.6.2 Japan Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Human Oocyte Cryopreservation Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Human Oocyte Cryopreservation Sales Value, 2019-2030
        6.7.2 South Korea Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Human Oocyte Cryopreservation Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Human Oocyte Cryopreservation Sales Value, 2019-2030
        6.8.2 Southeast Asia Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Human Oocyte Cryopreservation Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Human Oocyte Cryopreservation Sales Value, 2019-2030
        6.9.2 India Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Human Oocyte Cryopreservation Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Anova Fertility
        7.1.1 Anova Fertility Profile
        7.1.2 Anova Fertility Main Business
        7.1.3 Anova Fertility Human Oocyte Cryopreservation Products, Services and Solutions
        7.1.4 Anova Fertility Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.1.5 Anova Fertility Recent Developments
    7.2 CCRM IVF
        7.2.1 CCRM IVF Profile
        7.2.2 CCRM IVF Main Business
        7.2.3 CCRM IVF Human Oocyte Cryopreservation Products, Services and Solutions
        7.2.4 CCRM IVF Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.2.5 CCRM IVF Recent Developments
    7.3 Chill
        7.3.1 Chill Profile
        7.3.2 Chill Main Business
        7.3.3 Chill Human Oocyte Cryopreservation Products, Services and Solutions
        7.3.4 Chill Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.3.5 Chill Recent Developments
    7.4 CREATE Fertility
        7.4.1 CREATE Fertility Profile
        7.4.2 CREATE Fertility Main Business
        7.4.3 CREATE Fertility Human Oocyte Cryopreservation Products, Services and Solutions
        7.4.4 CREATE Fertility Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.4.5 CREATE Fertility Recent Developments
    7.5 Extend Fertility
        7.5.1 Extend Fertility Profile
        7.5.2 Extend Fertility Main Business
        7.5.3 Extend Fertility Human Oocyte Cryopreservation Products, Services and Solutions
        7.5.4 Extend Fertility Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.5.5 Extend Fertility Recent Developments
    7.6 HRC Fertility
        7.6.1 HRC Fertility Profile
        7.6.2 HRC Fertility Main Business
        7.6.3 HRC Fertility Human Oocyte Cryopreservation Products, Services and Solutions
        7.6.4 HRC Fertility Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.6.5 HRC Fertility Recent Developments
    7.7 IVF Australia
        7.7.1 IVF Australia Profile
        7.7.2 IVF Australia Main Business
        7.7.3 IVF Australia Human Oocyte Cryopreservation Products, Services and Solutions
        7.7.4 IVF Australia Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.7.5 IVF Australia Recent Developments
    7.8 Kindbody
        7.8.1 Kindbody Profile
        7.8.2 Kindbody Main Business
        7.8.3 Kindbody Human Oocyte Cryopreservation Products, Services and Solutions
        7.8.4 Kindbody Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.8.5 Kindbody Recent Developments
    7.9 London Women’s Clinic
        7.9.1 London Women’s Clinic Profile
        7.9.2 London Women’s Clinic Main Business
        7.9.3 London Women’s Clinic Human Oocyte Cryopreservation Products, Services and Solutions
        7.9.4 London Women’s Clinic Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.9.5 London Women’s Clinic Recent Developments
    7.10 Manchester Fertility
        7.10.1 Manchester Fertility Profile
        7.10.2 Manchester Fertility Main Business
        7.10.3 Manchester Fertility Human Oocyte Cryopreservation Products, Services and Solutions
        7.10.4 Manchester Fertility Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.10.5 Manchester Fertility Recent Developments
    7.11 Mayo Clinic
        7.11.1 Mayo Clinic Profile
        7.11.2 Mayo Clinic Main Business
        7.11.3 Mayo Clinic Human Oocyte Cryopreservation Products, Services and Solutions
        7.11.4 Mayo Clinic Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.11.5 Mayo Clinic Recent Developments
    7.12 Melbourne IVF
        7.12.1 Melbourne IVF Profile
        7.12.2 Melbourne IVF Main Business
        7.12.3 Melbourne IVF Human Oocyte Cryopreservation Products, Services and Solutions
        7.12.4 Melbourne IVF Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.12.5 Melbourne IVF Recent Developments
    7.13 Monash IVF
        7.13.1 Monash IVF Profile
        7.13.2 Monash IVF Main Business
        7.13.3 Monash IVF Human Oocyte Cryopreservation Products, Services and Solutions
        7.13.4 Monash IVF Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.13.5 Monash IVF Recent Developments
    7.14 Pacific Fertility Center-Los Angeles (PFCLA)
        7.14.1 Pacific Fertility Center-Los Angeles (PFCLA) Profile
        7.14.2 Pacific Fertility Center-Los Angeles (PFCLA) Main Business
        7.14.3 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Products, Services and Solutions
        7.14.4 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.14.5 Pacific Fertility Center-Los Angeles (PFCLA) Recent Developments
    7.15 PIVET
        7.15.1 PIVET Profile
        7.15.2 PIVET Main Business
        7.15.3 PIVET Human Oocyte Cryopreservation Products, Services and Solutions
        7.15.4 PIVET Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.15.5 PIVET Recent Developments
    7.16 Prelude Fertility
        7.16.1 Prelude Fertility Profile
        7.16.2 Prelude Fertility Main Business
        7.16.3 Prelude Fertility Human Oocyte Cryopreservation Products, Services and Solutions
        7.16.4 Prelude Fertility Human Oocyte Cryopreservation Revenue (US$ Million) & (2019-2024)
        7.16.5 Prelude Fertility Recent Developments

 8 Industry Chain Analysis
    8.1 Human Oocyte Cryopreservation Industrial Chain
    8.2 Human Oocyte Cryopreservation Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Human Oocyte Cryopreservation Sales Model
        8.5.2 Sales Channel
        8.5.3 Human Oocyte Cryopreservation Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Human Oocyte Cryopreservation Market Trends
 Table 2. Human Oocyte Cryopreservation Market Drivers & Opportunity
 Table 3. Human Oocyte Cryopreservation Market Challenges
 Table 4. Human Oocyte Cryopreservation Market Restraints
 Table 5. Global Human Oocyte Cryopreservation Revenue by Company (2019-2024) & (US$ Million)
 Table 6. Global Human Oocyte Cryopreservation Revenue Market Share by Company (2019-2024)
 Table 7. Key Companies Human Oocyte Cryopreservation Manufacturing Base Distribution and Headquarters
 Table 8. Key Companies Human Oocyte Cryopreservation Product Type
 Table 9. Key Companies Time to Begin Mass Production of Human Oocyte Cryopreservation
 Table 10. Global Human Oocyte Cryopreservation Companies Market Concentration Ratio (CR5 and HHI)
 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Oocyte Cryopreservation as of 2023)
 Table 12. Mergers & Acquisitions, Expansion Plans
 Table 13. Global Human Oocyte Cryopreservation Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
 Table 14. Global Human Oocyte Cryopreservation Sales Value by Type (2019-2024) & (US$ Million)
 Table 15. Global Human Oocyte Cryopreservation Sales Value by Type (2025-2030) & (US$ Million)
 Table 16. Global Human Oocyte Cryopreservation Sales Market Share in Value by Type (2019-2024)
 Table 17. Global Human Oocyte Cryopreservation Sales Market Share in Value by Type (2025-2030)
 Table 18. Global Human Oocyte Cryopreservation Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
 Table 19. Global Human Oocyte Cryopreservation Sales Value by Application (2019-2024) & (US$ Million)
 Table 20. Global Human Oocyte Cryopreservation Sales Value by Application (2025-2030) & (US$ Million)
 Table 21. Global Human Oocyte Cryopreservation Sales Market Share in Value by Application (2019-2024)
 Table 22. Global Human Oocyte Cryopreservation Sales Market Share in Value by Application (2025-2030)
 Table 23. Global Human Oocyte Cryopreservation Sales Value by Region, (2019 VS 2023 VS 2030) & (US$ Million)
 Table 24. Global Human Oocyte Cryopreservation Sales Value by Region (2019-2024) & (US$ Million)
 Table 25. Global Human Oocyte Cryopreservation Sales Value by Region (2025-2030) & (US$ Million)
 Table 26. Global Human Oocyte Cryopreservation Sales Value by Region (2019-2024) & (%)
 Table 27. Global Human Oocyte Cryopreservation Sales Value by Region (2025-2030) & (%)
 Table 28. Key Countries/Regions Human Oocyte Cryopreservation Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
 Table 29. Key Countries/Regions Human Oocyte Cryopreservation Sales Value, (2019-2024) & (US$ Million)
 Table 30. Key Countries/Regions Human Oocyte Cryopreservation Sales Value, (2025-2030) & (US$ Million)
 Table 31. Anova Fertility Basic Information List
 Table 32. Anova Fertility Description and Business Overview
 Table 33. Anova Fertility Human Oocyte Cryopreservation Products, Services and Solutions
 Table 34. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Anova Fertility (2019-2024)
 Table 35. Anova Fertility Recent Developments
 Table 36. CCRM IVF Basic Information List
 Table 37. CCRM IVF Description and Business Overview
 Table 38. CCRM IVF Human Oocyte Cryopreservation Products, Services and Solutions
 Table 39. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of CCRM IVF (2019-2024)
 Table 40. CCRM IVF Recent Developments
 Table 41. Chill Basic Information List
 Table 42. Chill Description and Business Overview
 Table 43. Chill Human Oocyte Cryopreservation Products, Services and Solutions
 Table 44. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Chill (2019-2024)
 Table 45. Chill Recent Developments
 Table 46. CREATE Fertility Basic Information List
 Table 47. CREATE Fertility Description and Business Overview
 Table 48. CREATE Fertility Human Oocyte Cryopreservation Products, Services and Solutions
 Table 49. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of CREATE Fertility (2019-2024)
 Table 50. CREATE Fertility Recent Developments
 Table 51. Extend Fertility Basic Information List
 Table 52. Extend Fertility Description and Business Overview
 Table 53. Extend Fertility Human Oocyte Cryopreservation Products, Services and Solutions
 Table 54. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Extend Fertility (2019-2024)
 Table 55. Extend Fertility Recent Developments
 Table 56. HRC Fertility Basic Information List
 Table 57. HRC Fertility Description and Business Overview
 Table 58. HRC Fertility Human Oocyte Cryopreservation Products, Services and Solutions
 Table 59. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of HRC Fertility (2019-2024)
 Table 60. HRC Fertility Recent Developments
 Table 61. IVF Australia Basic Information List
 Table 62. IVF Australia Description and Business Overview
 Table 63. IVF Australia Human Oocyte Cryopreservation Products, Services and Solutions
 Table 64. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of IVF Australia (2019-2024)
 Table 65. IVF Australia Recent Developments
 Table 66. Kindbody Basic Information List
 Table 67. Kindbody Description and Business Overview
 Table 68. Kindbody Human Oocyte Cryopreservation Products, Services and Solutions
 Table 69. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Kindbody (2019-2024)
 Table 70. Kindbody Recent Developments
 Table 71. London Women’s Clinic Basic Information List
 Table 72. London Women’s Clinic Description and Business Overview
 Table 73. London Women’s Clinic Human Oocyte Cryopreservation Products, Services and Solutions
 Table 74. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of London Women’s Clinic (2019-2024)
 Table 75. London Women’s Clinic Recent Developments
 Table 76. Manchester Fertility Basic Information List
 Table 77. Manchester Fertility Description and Business Overview
 Table 78. Manchester Fertility Human Oocyte Cryopreservation Products, Services and Solutions
 Table 79. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Manchester Fertility (2019-2024)
 Table 80. Manchester Fertility Recent Developments
 Table 81. Mayo Clinic Basic Information List
 Table 82. Mayo Clinic Description and Business Overview
 Table 83. Mayo Clinic Human Oocyte Cryopreservation Products, Services and Solutions
 Table 84. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Mayo Clinic (2019-2024)
 Table 85. Mayo Clinic Recent Developments
 Table 86. Melbourne IVF Basic Information List
 Table 87. Melbourne IVF Description and Business Overview
 Table 88. Melbourne IVF Human Oocyte Cryopreservation Products, Services and Solutions
 Table 89. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Melbourne IVF (2019-2024)
 Table 90. Melbourne IVF Recent Developments
 Table 91. Monash IVF Basic Information List
 Table 92. Monash IVF Description and Business Overview
 Table 93. Monash IVF Human Oocyte Cryopreservation Products, Services and Solutions
 Table 94. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Monash IVF (2019-2024)
 Table 95. Monash IVF Recent Developments
 Table 96. Pacific Fertility Center-Los Angeles (PFCLA) Basic Information List
 Table 97. Pacific Fertility Center-Los Angeles (PFCLA) Description and Business Overview
 Table 98. Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Products, Services and Solutions
 Table 99. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Pacific Fertility Center-Los Angeles (PFCLA) (2019-2024)
 Table 100. Pacific Fertility Center-Los Angeles (PFCLA) Recent Developments
 Table 101. PIVET Basic Information List
 Table 102. PIVET Description and Business Overview
 Table 103. PIVET Human Oocyte Cryopreservation Products, Services and Solutions
 Table 104. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of PIVET (2019-2024)
 Table 105. PIVET Recent Developments
 Table 106. Prelude Fertility Basic Information List
 Table 107. Prelude Fertility Description and Business Overview
 Table 108. Prelude Fertility Human Oocyte Cryopreservation Products, Services and Solutions
 Table 109. Revenue (US$ Million) in Human Oocyte Cryopreservation Business of Prelude Fertility (2019-2024)
 Table 110. Prelude Fertility Recent Developments
 Table 111. Key Raw Materials Lists
 Table 112. Raw Materials Key Suppliers Lists
 Table 113. Human Oocyte Cryopreservation Downstream Customers
 Table 114. Human Oocyte Cryopreservation Distributors List
 Table 115. Research Programs/Design for This Report
 Table 116. Key Data Information from Secondary Sources
 Table 117. Key Data Information from Primary Sources
 Table 118. Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Human Oocyte Cryopreservation Product Picture
 Figure 2. Global Human Oocyte Cryopreservation Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Human Oocyte Cryopreservation Sales Value (2019-2030) & (US$ Million)
 Figure 4. Human Oocyte Cryopreservation Report Years Considered
 Figure 5. Global Human Oocyte Cryopreservation Players Revenue Ranking (2023) & (US$ Million)
 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Human Oocyte Cryopreservation Revenue in 2023
 Figure 7. Human Oocyte Cryopreservation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 8. Slow-cooling Method Picture
 Figure 9. Flash-freezing Process (Vitrification) Picture
 Figure 10. Global Human Oocyte Cryopreservation Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 11. Global Human Oocyte Cryopreservation Sales Value Market Share by Type, 2023 & 2030
 Figure 12. Product Picture of 25-30 Year Old Female
 Figure 13. Product Picture of 30-35 Year Old Female
 Figure 14. Product Picture of 35-40 Year Old Female
 Figure 15. Product Picture of Others
 Figure 16. Global Human Oocyte Cryopreservation Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 17. Global Human Oocyte Cryopreservation Sales Value Market Share by Application, 2023 & 2030
 Figure 18. North America Human Oocyte Cryopreservation Sales Value (2019-2030) & (US$ Million)
 Figure 19. North America Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030
 Figure 20. Europe Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 21. Europe Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030
 Figure 22. Asia Pacific Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 23. Asia Pacific Human Oocyte Cryopreservation Sales Value by Region (%), 2023 VS 2030
 Figure 24. South America Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 25. South America Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030
 Figure 26. Middle East & Africa Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 27. Middle East & Africa Human Oocyte Cryopreservation Sales Value by Country (%), 2023 VS 2030
 Figure 28. Key Countries/Regions Human Oocyte Cryopreservation Sales Value (%), (2019-2030)
 Figure 29. United States Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 30. United States Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
 Figure 31. United States Human Oocyte Cryopreservation Sales Value by Application (%), 2023 VS 2030
 Figure 32. Europe Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 33. Europe Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
 Figure 34. Europe Human Oocyte Cryopreservation Sales Value by Application (%), 2023 VS 2030
 Figure 35. China Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 36. China Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
 Figure 37. China Human Oocyte Cryopreservation Sales Value by Application (%), 2023 VS 2030
 Figure 38. Japan Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 39. Japan Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
 Figure 40. Japan Human Oocyte Cryopreservation Sales Value by Application (%), 2023 VS 2030
 Figure 41. South Korea Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 42. South Korea Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
 Figure 43. South Korea Human Oocyte Cryopreservation Sales Value by Application (%), 2023 VS 2030
 Figure 44. Southeast Asia Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 45. Southeast Asia Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
 Figure 46. Southeast Asia Human Oocyte Cryopreservation Sales Value by Application (%), 2023 VS 2030
 Figure 47. India Human Oocyte Cryopreservation Sales Value, (2019-2030) & (US$ Million)
 Figure 48. India Human Oocyte Cryopreservation Sales Value by Type (%), 2023 VS 2030
 Figure 49. India Human Oocyte Cryopreservation Sales Value by Application (%), 2023 VS 2030
 Figure 50. Human Oocyte Cryopreservation Industrial Chain
 Figure 51. Human Oocyte Cryopreservation Manufacturing Cost Structure
 Figure 52. Channels of Distribution (Direct Sales, and Distribution)
 Figure 53. Bottom-up and Top-down Approaches for This Report
 Figure 54. Data Triangulation
 Figure 55. Key Executives Interviewed

Description

The global market for Human Oocyte Cryopreservation was estimated to be worth US$ 82 million in 2023 and is forecast to a readjusted size of US$ 210 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030.

Human oocyte cryopreservation (egg freezing) is a procedure to preserve female eggs (oocytes). The eggs are extracted, frozen and stored. The purpose of the procedure is to give women the option of thawing, fertilizing and transplanting the eggs into the uterus as embryos to promote future pregnancy.

Oocyte cryopreservation refers to the technology of cooling human oocytes and storing them in liquid nitrogen (generally stored in liquid nitrogen at -196°C), resuscitating (thawing) them when needed, and ensuring that the oocytes are alive and functioning normally. It is a derivative technology of assisted reproductive technology, mainly used to treat infertility and preserve female fertility.

The driving factors of the oocyte cryopreservation market mainly include the following aspects:
Technological progress
The continuous improvement and maturity of oocyte cryopreservation technology has improved the recovery rate and survival rate of frozen oocytes, thereby increasing the clinical application prospects of this technology and driving the development of the market.

Changes in fertility concepts
The changes in modern women's fertility concepts and the intensification of the trend of late marriage and late childbearing have led more and more women to choose oocyte cryopreservation technology to maintain fertility and provide guarantees for future fertility plans.

Growth in medical demand
With the improvement of medical standards and people's attention to reproductive health, more and more medical institutions and patients have begun to pay attention to oocyte cryopreservation technology, which has promoted the rapid development of the market.

Policy support
The support policies of some countries and regions for assisted reproductive technology, as well as the improvement of relevant laws and regulations, have provided a good policy environment for the development of oocyte cryopreservation technology.

Unlike sperm, oocytes are larger and contain a lot of water, which makes it easier to form ice crystals that may damage the eggs during the freezing process. In addition, egg extraction is not easy and the number is scarce, so the selection of protective agents during the freezing process is also more demanding. These factors have made egg freezing one of the difficulties in freezing technology.

However, with the continuous advancement of technology, the success rate of oocyte cryopreservation has been significantly improved. International clinical trials have proven that frozen eggs can be stored for at least ten years, and they still have the ability to conceive after thawing, can form healthy embryos, and can normally conceive babies. This has led more and more women to choose to preserve their future reproductive ability through oocyte cryopreservation technology, that is, to buy a "fertility insurance".

In general, oocyte cryopreservation technology provides an effective option for women who want to preserve their fertility, and also provides new possibilities for the development of assisted reproductive technology.

The Human Oocyte Cryopreservation market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Oocyte Cryopreservation.

Market Segmentation